<DOC>
	<DOC>NCT03106259</DOC>
	<brief_summary>Observational Study to evaluate the safety of FURESTEM-RA lnj. in moderate to severe rheumatoid arthritis patients who participated in phase 1 clinical trial of FURESTEM-RA lnj.</brief_summary>
	<brief_title>Observational Study to Assess the Safety of FURESTEM-RA Lnj. In Patients With Moderate to Severe Rheumatoid Arthritis</brief_title>
	<detailed_description>This is a observational study, single center, open label, study of safety of FURESTEM-RA Inj. in subjects with moderate to severe rheumatoid arthritis. Subjects participating in this observational study originally participated in study FURESTEM-RA Inj. [NCT02221258]</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Subjects participating in this observational study originally participated in study FURESTEMRA Inj.[NCT02221258] Subject who understands and voluntarily sign an informed consent form In case followup is not possible from end of clinical trial Phase 1 to end of this study period</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>FURESTEM-RA</keyword>
</DOC>